Angiotensin-(1-7) receptor Mas agonist ameliorates progress of atherosclerosis in apoE-knockout mice

Journal of Physiology and Pharmacology

Volumn 63, Issue 1, 2012, Pages 77-85

  Jawien, J ^a   Toton Zuranska, J ^a   Gajda, M ^a   Niepsuj, A ^a   Gebska, A ^a   Kus, K ^a   Suski, M ^a   Pyka Fosciak, G ^a   Nowak, B ^a   Guzik, T J ^a   Marcinkiewicz, J ^a   Olszanecki, R ^a   Korbut, R ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Angiotensin (1 7); ApoE knockout mice; Atherosclerosis; AVE 0991; Cholesterol; Renin angiotensin system; Triglycerides

Indexed keywords

ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; APOLIPOPROTEIN E; B7 ANTIGEN; CD40 ANTIGEN; CD69 ANTIGEN; CD86 ANTIGEN; GLYCOPROTEIN P 15095; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 12; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; PERINDOPRIL; SERUM AMYLOID A; THIORPHAN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ROOT; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DENDRITIC CELL; DRUG STRUCTURE; FEMALE; FLOW CYTOMETRY; GENE; KNOCKOUT MOUSE; MACROPHAGE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; P22PHOX GENE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANGIOTENSIN I; ANIMALS; ANTIGENS, CD; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; IMIDAZOLES; LIPIDS; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; PERINDOPRIL; PROTO-ONCOGENE PROTEINS; RECEPTORS, ANGIOTENSIN; RECEPTORS, G-PROTEIN-COUPLED; THIORPHAN;

EID: 84859135623     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Mendez-Fernandez YV, Stevenson BG, Diehl CJ, et al. The inhibitory FcγRIIb modulates the inflammatory response and influences atherosclerosis in male apoE(-/-) mice. Atherosclerosis 2011; 214: 73-80.
2. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011; 12: 204-212.
3. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
4. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91: 281-291.
5. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000; 105: 1605-1612.
6. Montecucco F, Pende A, Mach F. The renin-angiotensin systemmodulatesinflammatoryprocessesin atherosclerosis: evidence from basic research and clinical studies. Mediators Inflamm 2009; 2009: 752406.
7. Toton-Zuranska J, Gajda M, Pyka-Fosciak G, et al. AVE 0991-angiotensin-(1-7)receptoragonist,inhibits atherogenesis in apoE-knockout mice. J Physiol Pharmacol 2010; 61: 181-183.
8. Jawien J, Nastalek P, Korbut R. Mouse models of experimental atherosclerosis. J Physiol Pharmacol 2004; 55: 503-517.
9. Jawien J, Csanyi G, Gajda M, et al. Ticlopidine attenuates progression of atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice. Eur J Pharmacol 2007; 556: 129-135.
10. Szczeklik A, Jawien J. Immunoglobulin E in acute phase response to surgical stress. Clin Exp Allergy 1996; 26: 303-307.
11. Elhage R, Gourdy P, Jawien J, et al. The atheroprotective effect of 17β-estradiol depends on complex interactions in adaptive immunity. Am J Pathol 2005; 167: 267-274.
12. Jawien J, Gajda M, Wolkow PP, Zuranska J, Olszanecki R, Korbut R. The effect of montelukast on atherogenesis in apoE/LDLR - double knockout mice. J Physiol Pharmacol 2008; 59: 633-639.
13. Kus K, Gajda M, Pyka-Fosciak G, et al. The effect of nebivolol on atherogenesis in apoE - knockout mice. J Physiol Pharmacol 2009; 60: 163-165.
14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 22DDCT Method. Methods 2001; 25: 402-408.
15. Zack M, Boyanovsky BB, Shridas P, et al. Group X secretory phospholipase A(2) augments angiotensin II- induced inflammatory responses and abdominal aortic aneurysm formation in apoE-deficient mice. Atherosclerosis 2011; 214: 58-64.
16. McAfee JG, Subramanian G, Gagne G. Technique of leukocyte harvesting and labeling: problems and perspectives. Semin Nucl Med 1984; 14: 83-106.
17. Chattopadhyay PK. Quantum dot technology in flow cytometry. Methods Cell Biol 2011; 102: 463-477.
18. Arnal JF, Castano C, Maupas E, Mugniot A, et al. Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice. Atherosclerosis 2001; 155: 291-295.
19. Candido R, Jandeleit-Dahm KA, Cao Z, et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 2002; 106: 246-253.
20. Da Cunha V, Tham DM, Martin-McNulty B, et al. Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis 2005; 178: 9-17.
21. Hayek T, Attias J, Coleman R, et al. The angiotensinconverting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovasc Res 1999; 44: 579-587.
22. Keidar S, Attias J, Coleman R, Wirth K, Scholkens B, Hayek T. Attenuation of atherosclerosis in apolipoprotein E- deficient mice by ramipril is dissociated from its antihypertensive effect and from potentiation of bradykinin. J Cardiovasc Pharmacol 2000; 35: 64-72.
23. Knowles JW, Reddick RL, Jennette JC, Shesely EG, Smithies O, Maeda N. Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-) apoE(-/-) mice are ameliorated by enalapril treatment. J Clin Invest 2000; 105: 451-458.
24. Violi F, Basili S, Nigro C, Pignatelli P. Role of NADPH oxidase in atherosclerosis. Future Cardiol 2009; 5: 83-92.
25. Buono C, Pang H, Uchida Y, Libby P, Sharpe AH, Lichtman AH. B7-1/B7-2 costimulation regulates plaque antigen- specific T-cell responses and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 2004; 109: 2009-2015.
26. Lutgens E, Lievens D, Beckers L, Donners M, Daemen M. CD40 and its ligand in atherosclerosis. Trends Cardiovasc Med 2007; 17: 118-123.
27. Daugherty A, Cassis L. Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor mice. Ann NY Acad Sci 1999; 892: 108-118.
28. Santos RA, Brosnihan KB, Chappell MC, et al. Converting enzyme activity and angiotensin metabolism in the dog brainstem. Hypertension 1988; 11(2 Pt 2): I 153-157.
29. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1-E9.
30. Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003; 100: 8258-8263.
31. Chappell MC. Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure? Hypertension 2007; 50: 596-599.
32. Iusuf D, Henning RH, van Gilst WH, Roks AJ. Angiotensin (1-7): pharmacological properties and pharmacotherapeutic perspectives. Eur J Pharmacol 2008; 585: 303-312.
33. Santos RA, Campagnole-Santos MJ, Andrade SP. Angiotensin-(1-7): an update. Regul Pept 2000; 91: 45-62.
34. Benter IF, Yousif MH, Cojocel C, Al-Maghrebi M, Diz DI. Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am J Physiol Heart Circ Physiol 2007; 292: H666-H672.
35. Kucharewicz I, Pawlak R, Matys T, Pawlak D, Buczko W. Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7). Hypertension 2002; 40: 774-779.
36. Tesanovic S, Vinh A, Gaspari TA, Casley D, Widdop RE. Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2010; 30: 1606-1613.
37. Wiemer G, Dobrucki LW, Louka FR, Malinski T, Heitsch H. AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension 2002; 40: 847-852.
38. Benter IF, Yousif MH, Dhaunsi GS, Kaur J, Chappell MC, Diz DI. Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am J Nephrol 2008; 28: 25-33.
39. Gomez M, Sanz-Gonzalez SM, Abu Nabah YN, Lamana A, Sanchez-Madrid F, Andres V. Atherosclerosis development in apolipoprotein E-null mice deficient for CD69. Cardiovasc Res 2009; 81: 197-205.
40. Iwai M, Horiuchi M. Devil and angel in the rennin angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. Hypertens Res 2009; 32: 533-536.
41. Castro CH, Santos RA, Ferreira AJ, Bader M, Alenina N, Almeida AP. Evidence for a functional interaction of the angiotensin-(1-7) receptor Mas with AT1 and AT2 receptors in the mouse heart. Hypertension 2005; 46: 937-942.
42. Kramkowski K, Mogielnicki A, Leszczynska A, Buczko W. Angiotensin-(1-9), the product of angiotensin I conversion in platelets, enhances arterial thrombosis in rats. J Physiol Pharmacol 2010; 61: 317-324.
43. Iyer SN, Ferrario CM, Chappell MC. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 1998; 31: 356-361.
44. Luque M, Martin P, Martell N, Fernandez C, Brosnihan KB, Ferrario CM. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens 1996; 14: 799-805.
45. Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005; 111: 2605-2610.
46. Keidar S, Gamliel-Lazarovich A, Kaplan M, et al. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circ Res 2005; 97: 946-953.
47. Szczepanska-Sadowska E, Cudnoch-Jedrzejewska A, Ufnal M, Zera T. Brain and cardiovascular diseases: common neurogenic background of cardiovascular, metabolic and inflammatory diseases. J Physiol Pharmacol 2010; 61: 509-521.
48. Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and functional roles of angiotensin converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol 2005; 289: H2281-H2290.
49. Raizada MK, Ferreira AJ. ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol 2007; 50: 112-119.